158 related articles for article (PubMed ID: 16793737)
1. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML.
Litzow MR; Dietz AB; Bulur PA; Butler GW; Gastineau DA; Hoering A; Fink SR; Letendre L; Padley DJ; Paternoster SF; Tefferi A; Vuk-Pavlović S
Cytotherapy; 2006; 8(3):290-8. PubMed ID: 16793737
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
Westermann J; Kopp J; van Lessen A; Hecker AC; Baskaynak G; le Coutre P; Döhner K; Döhner H; Dörken B; Pezzutto A
Br J Haematol; 2007 May; 137(4):297-306. PubMed ID: 17408402
[TBL] [Abstract][Full Text] [Related]
3. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
Van Driessche A; Van de Velde AL; Nijs G; Braeckman T; Stein B; De Vries JM; Berneman ZN; Van Tendeloo VF
Cytotherapy; 2009; 11(5):653-68. PubMed ID: 19530029
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
[TBL] [Abstract][Full Text] [Related]
5. Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy.
Choi BH; Kang HK; Park JS; Kim SK; Pham TN; Zhu XW; Cho D; Nam JH; Chung IJ; Kim YJ; Rhee JH; Kim HJ; Lee JJ
J Clin Apher; 2006 Dec; 21(4):233-40. PubMed ID: 17120232
[TBL] [Abstract][Full Text] [Related]
6. Serum-free culture of dendritic cells from patients with chronic myeloid leukemia in vitro and estimation of their cytotoxicity.
Zhao W; Xing P; Wei X; Wang T; Yang D; Li M
Chin Med J (Engl); 2002 Sep; 115(9):1296-300. PubMed ID: 12411098
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.
Boissel N; Rousselot P; Raffoux E; Cayuela JM; Soulier J; Mooney N; Charron D; Dombret H; Toubert A; Rea D
J Leukoc Biol; 2006 Apr; 79(4):747-56. PubMed ID: 16461746
[TBL] [Abstract][Full Text] [Related]
8. [Effects of ST1571 on the development of dendritic cells derived from bone marrow mononuclear cells in patients with chronic myeloid leukemia].
Zheng SE; Jin J; Tong XM; Qian WB; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):920-3. PubMed ID: 17533744
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell-based immunogens for B-cell chronic lymphocytic leukemia.
Allgeier T; Garhammer S; Nössner E; Wahl U; Kronenberger K; Dreyling M; Hallek M; Mocikat R
Cancer Lett; 2007 Jan; 245(1-2):275-83. PubMed ID: 16516377
[TBL] [Abstract][Full Text] [Related]
10. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia.
Li Z; Qiao Y; Liu B; Laska EJ; Chakravarthi P; Kulko JM; Bona RD; Fang M; Hegde U; Moyo V; Tannenbaum SH; Ménoret A; Gaffney J; Glynn L; Runowicz CD; Srivastava PK
Clin Cancer Res; 2005 Jun; 11(12):4460-8. PubMed ID: 15958631
[TBL] [Abstract][Full Text] [Related]
11. Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells.
Dietz AB; Bulur PA; Erickson MR; Wettstein PJ; Litzow MR; Wyatt WA; Dewald GW; Tefferi A; Pankratz VS; Vuk-Pavlović S
J Hematother Stem Cell Res; 2000 Feb; 9(1):95-101. PubMed ID: 10738977
[TBL] [Abstract][Full Text] [Related]
12. Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation.
Orsini E; Calabrese E; Maggio R; Pasquale A; Nanni M; Trasarti S; Tafuri A; Guarini A; Foa R
Leuk Res; 2006 Jul; 30(7):785-94. PubMed ID: 16527350
[TBL] [Abstract][Full Text] [Related]
13. [Effect of autologous dendritic cells on chronic myeloid leukemia cells in vitro].
Li Y; Yang Y; Li S; Meng W; Ding X; Wu Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):47-50. PubMed ID: 15600177
[TBL] [Abstract][Full Text] [Related]
14. Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells.
Rapoport AP; Levine BL; Badros A; Meisenberg B; Ruehle K; Nandi A; Rollins S; Natt S; Ratterree B; Westphal S; Mann D; June CH
Bone Marrow Transplant; 2004 Jan; 33(1):53-60. PubMed ID: 14578928
[TBL] [Abstract][Full Text] [Related]
15. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of leukemia-derived dendritic cells: preclinical and clinical progress.
Claxton DF; McMannis J; Champlin R; Choudhury A
Crit Rev Immunol; 2001; 21(1-3):147-55. PubMed ID: 11642601
[TBL] [Abstract][Full Text] [Related]
17. Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients.
Bertazzoli C; Marchesi E; Passoni L; Barni R; Ravagnani F; Lombardo C; Corneo GM; Pioltelli P; Pogliani E; Gambacorti-Passerini C
Clin Cancer Res; 2000 May; 6(5):1931-5. PubMed ID: 10815918
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
[TBL] [Abstract][Full Text] [Related]
19. Multicenter study on in vitro characterization of dendritic cells.
Eichler H; Nguyen XD; Roelen D; Celluzzi CM; McKenna D; Pamphilon D; Blair A; Read EJ; Takahashi TA; Szczepiorkowski ZM;
Cytotherapy; 2008; 10(1):21-9. PubMed ID: 18202971
[TBL] [Abstract][Full Text] [Related]
20. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
Schmitt M; Li L; Giannopoulos K; Chen J; Brunner C; Barth T; Schmitt A; Wiesneth M; Döhner K; Döhner H; Greiner J
Exp Hematol; 2006 Dec; 34(12):1709-19. PubMed ID: 17157168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]